Sharma Rohit, Kumar Sourabh, Komal Kumari, Ghosh Rashmi, Thakur Shubham, Pal Ravi Raj, Kumar Manish
Department of Pharmaceutics, ISF College Pharmacy, GT Road, Moga, 142001, Punjab, India.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 9. doi: 10.1007/s00210-025-04094-y.
Pancreatic cancer is one of the most lethal malignancies worldwide. It is characterized by poor prognosis, high mortality, and recurrence rates. Various modifiable and non-modifiable risk factors are associated with pancreatic cancer incidence. Available treatments for pancreatic cancer include surgery, chemotherapy, radiotherapy, photodynamic therapy, supportive care, targeted therapy, and immunotherapy. However, the survival rates for PC are very low. Regrettably, despite efforts to enhance prognosis, the survival rate of pancreatic cancer remains relatively low. Therefore, it is essential to investigate new approaches to improve pancreatic cancer treatment. By synthesizing current knowledge and identifying existing gaps, this article provides a comprehensive overview of risk factors, pathology, conventional treatments, targeted therapies, and recent advancements in nanocarriers for its treatment, along with various clinical trials and patents that justify the safety and efficacy of innovative carriers for drug delivery systems. Ultimately, this review underscores the potential of these innovative formulations to improve outcomes and contribute significantly to the advancement of Pancreatic Cancer treatment. Together, these insights highlight nano-formulations as a promising frontier for effectively treating Pancreatic Cancer.
胰腺癌是全球最致命的恶性肿瘤之一。其特点是预后差、死亡率高和复发率高。多种可改变和不可改变的风险因素与胰腺癌的发病有关。胰腺癌的现有治疗方法包括手术、化疗、放疗、光动力疗法、支持治疗、靶向治疗和免疫治疗。然而，胰腺癌的生存率非常低。遗憾的是，尽管人们努力改善预后，但胰腺癌的生存率仍然相对较低。因此，研究改善胰腺癌治疗的新方法至关重要。通过综合现有知识并找出存在的差距，本文全面概述了风险因素、病理学、传统治疗方法、靶向治疗以及用于其治疗的纳米载体的最新进展，以及各种临床试验和专利，这些都证明了创新载体用于药物递送系统的安全性和有效性。最终，本综述强调了这些创新制剂改善治疗结果的潜力，并为胰腺癌治疗的进展做出了重大贡献。总之，这些见解突出了纳米制剂作为有效治疗胰腺癌的一个有前景的前沿领域。
